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Like many Gram-negative pathogens, Shigella rely on a type three secretion system
(T3SS) for injection of effector proteins directly into eukaryotic host cells to initiate
and sustain infection. Protein secretion through the needle-like type three secretion
apparatus (T3SA) requires ATP hydrolysis by the T3SS ATPase Spa47, making it a
likely target for in vivo regulation of T3SS activity and an attractive target for
small molecule therapeutics against shigellosis. Here, we developed a model of an
activated Spa47 homo-hexamer, identifying two distinct regions at each protomer
interface that we hypothesized to provide intermolecular interactions supporting
Spa47 oligomerization and enzymatic activation. Mutational analysis and a series
of high-resolution crystal structures confirm the importance of these residues, as
many of the engineered mutants are unable to form oligomers and efficiently
hydrolyze ATP in vitro. Furthermore, in vivo evaluation of Shigella virulence phe-
notype uncovered a strong correlation between T3SS effector protein secretion,
host cell membrane disruption, and cellular invasion by the tested mutant strains,
suggesting that perturbation of the identified interfacial residues/interactions
influences Spa47 activity through preventing oligomer formation, which in turn
regulates Shigella virulence. The most impactful mutations are observed within
the conserved Site 2 interface where the native residues support oligomerization
and likely contribute to a complex hydrogen bonding network that organizes the
active site and supports catalysis. The critical reliance on these conserved resi-
dues suggests that aspects of T3SS regulation may also be conserved, providing
promise for the development of a cross-species therapeutic that broadly targets
T3SS ATPase oligomerization and activation.
K E YWORD S
ATPase, catalysis, oligomerization, Spa47, T3SS, type 3 secretion system, virulence regulation
Abbreviations: AEBSF, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride; BSA, bovine serum albumin; CBD, chitin binding domain; DMEM, Dulbecco's Modified Eagle Medium; DTT,
dithiothreitol; EDTA, ethylenediaminetetraacetic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IPTG, Isopropyl β-D-1-thiogalactopyranoside; LB, Luria-Bertani; LPS,
lipopolysaccharide; PBS, phosphate buffered saline; PDVF, polyvinylidene fluoride; PMF, proton motive force; RMSD, root-mean-square deviation; T3SA, type three secretion apparatus; T3SS,
type three secretion system; TB, terrific broth; TEM, transmission electron microscopy; TLC, thin layer chromatography; TSA, tryptic soy agar; TSB, tryptic soy broth.
†Authors contributed equally to this work.
Received: 10 April 2019 Revised: 23 May 2019 Accepted: 30 May 2019
DOI: 10.1002/prot.25754
Proteins. 2019;87:931–942. wileyonlinelibrary.com/journal/prot © 2019 Wiley Periodicals, Inc. 931
1 | INTRODUCTION
Shigella is a genus of nonmotile, facultative anaerobic, Gram-negative
bacteria belonging to the family Enterobacteriaceae. Infection by any
one of the four Shigella species results in shigellosis, a severe form of
bacillary dysentery hallmarked by colonic mucosal inflammation and
bloody diarrhea. The debilitating symptoms, low infectious dose
(10-100 organisms),1 and rapid emergence of antibiotic and multi-
antibiotic resistant strains result in an estimated 90 million annual
infections and more than 100 000 deaths per year, making Shigella a
worldwide health concern.2,3 The highest mortality rate, however, is
observed among children living in developing countries lacking access
to clean drinking water and proper medical care.4 With no FDA
approved vaccine against Shigella yet available, it is likely that without
active intervention, Shigella infections will continue to be one of the
leading bacterial causes of diarrheal disease and a significant global
health burden. These alarming factors underscore the urgent need to
better understand the molecular mechanisms responsible for activa-
tion and regulation of Shigella's primary virulence factor, the type
three secretion system (T3SS).
The T3SS is an elegant nanomachine shared by many Gram-
negative bacteria, including Shigella, Salmonella, Escherichia coli, Chla-
mydia, Yersinia, and others.5-7 Each of these pathogens is reliant on
their T3SS(s) as a primary virulence factor that injects an arsenal of
bacterial effector proteins directly into the host cell cytoplasm. While
the roles of the injected effector proteins are pathogen specific and
tailored to the pathogens' infective environments and replicative
niches, the effectors are all secreted through a highly conserved
needle-like type three secretion apparatus (T3SA) and generally sup-
port host cell infection and evasion of host immune responses.8
Kubori and colleagues first visualized negative-stained structures of
the T3SA via transmission electron microscopy (TEM) in 1998.9 These
original images and a more recent series of TEM and cryo-electron
tomography 3D structures clearly show that the T3SA consists of a
basal body that anchors the apparatus to the bacterial inner and outer
membranes, a hollow needle-like structure that extends from the basal
body past the membrane-associated lipopolysaccharide (LPS) layer, and
an associated protein complex that resides at the tip of the needle and
penetrates the eukaryotic host cell membrane.10-13 Additionally, several
of the most recent studies show that the T3SA contains a cytoplasmic
protein complex associated with the apparatus basal body and that this
complex includes a highly conserved homooligomeric ATPase that sup-
ports protein secretion through the apparatus.10,14 We have previously
demonstrated that the Shigella protein Spa47 is a T3SS ATPase whose
activity is essential for protein secretion through the apparatus and
overall Shigella virulence.15,16 Furthermore, Spa47 oligomerization is
required for ATPase activity, as residues from opposite sides of adja-
cent Spa47 protomers contribute to interfacial active sites within the
complex, making Spa47 oligomerization a likely means of regulating
T3SS activity in vivo and an attractive target for nonantibiotic thera-
peutics against Shigella infections.17
Here, we use a recently solved Spa47 crystal structure15 to develop
a homo-hexameric model of the activated Spa47 complex and identify
interfacial residues that are involved in Spa47 oligomerization. The
identified residues cluster to two independent sites at the interface
between Spa47 protomers where they appear to be involved in a com-
plex hydrogen bonding network that supports Spa47 oligomerization
and catalysis. Each of the identified residues was mutated to an oppo-
sitely charged amino acid as well as to alanine in an effort to disrupt
the predicted interactions. Indeed, several of the engineered mutations
had a significant negative influence on oligomer formation and enzyme
activity in vitro as well as T3SS activity and Shigella virulence pheno-
type in vivo. High-resolution crystal structures of ten of the Spa47
mutants verified the intended mutations and showed that the overall
integrity of the protein structure was unaffected, supporting our
hypothesis that the observed effects resulted from perturbed inter-
molecular interactions. Together, these findings begin to assemble an
important molecular description of Spa47 oligomerization and the influ-
ences it has on T3SS activity and Shigella virulence phenotype while
additionally identifying precise and highly-conserved targets for much
needed anti-infective therapeutics against T3SS ATPases.
2 | EXPERIMENTAL PROCEDURES
2.1 | Materials
Wild-type S. flexneri corresponds to the serotype 2a 2457T strain
originally isolated in 1954.18 The S. flexneri spa47 null strain was
engineered by Abdelmounaaïm Allaoui as described in Jouihri et al.19
E. coli strains and 2X ligation mix were from Novagen (Madison, WI).
Restriction enzymes, the pTYB21 protein expression plasmid, PCR
buffer, Phusion High-Fidelity polymerase, and chitin resin were pur-
chased from New England Biolabs (Ipswich, MA). Oligonucleotide
primers and the synthesized spa47 gene were from Integrated DNA
Technologies (Coralville, IA). Defibrinated sheep blood was from Colo-
rado Serum Company (Denver, CO), and HeLa cells were from the
American Type Culture Collection (Manassas, VA). The Superdex
200 Increase size-exclusion column and 5 mL HiTrapQ resin were pur-
chased from GE Healthcare (Pittsburgh, PA). ATP was from Sigma-
Aldrich (St. Louis, MO) and α-32P-ATP was from Perkin Elmer (Boston,
MA). Dithiothreitol (DTT) and ampicillin were from Gold Biotechnol-
ogy (St. Louis, MO). Rabbit anti-IpaC antibodies and the pWPsf4 plas-
mid were generous gifts from Wendy and William Picking (University
of Kansas). DyLight 488 conjugated mouse anti-glyceraldehyde
3-phosphate dehydrogenase and Alexa Fluor 647 goat anti-rabbit
antibodies were purchased from Thermo Scientific (Rockford, IL). All
other solutions and chemicals were of reagent grade. The UniProtKB
accession number for Spa47 is P0A1C1.
2.2 | Cloning
The spa47 gene was purchased as a double-stranded gBlock product
from Integrated DNA Technologies with modifications for cloning into
the expression plasmid pTYB21, which encodes an N-terminal chitin
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binding domain (CBD) and intein linker as described previously.16 Each
of the Spa47 point mutants described in this study was generated in
the expression plasmid pTYB21 using inverse PCR and the wild-type
spa47/pTYB21 construct as a template. Wild-type spa47 and each of
the tested mutants was additionally cloned into the plasmid pWPsf4
using primers that encode 5’ NdeI and 3’ BamHI restriction sites.
Spa47 constructs lacking the N-terminal 79 residues were generated
using inverse PCR and the spa47 mutants in pTYB21 as a template.
Primer sequences are available upon request. All constructs were
sequence verified by Sanger sequencing (Genewiz, Inc., South Plain-
field, NJ).
2.3 | Protein expression and purification
Spa47 and each of the Spa47 mutants encoded in pTYB21 were
transformed into E. coli Tuner (DE3) cells, expressed, and purified as
previously described.16 Briefly, the transformed E. coli cells were grown
to an OD600 of 0.8 in Terrific Broth media containing 0.1 mg/mL ampi-
cillin at 37C, 200 RPM. The culture was cooled to 17C and induced
with 1 mM IPTG for approximately 20 h (17C, 200 RPM). All subse-
quent steps were carried out at 4C (or on ice) unless otherwise stated.
The bacteria were pelleted by centrifugation, resuspended in binding
buffer (20 mM Tris, 500 mM NaCl, pH 7.9) containing 0.2 mM of the
protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochlo-
ride (AEBSF), lysed by sonication, and purified using a chitin affinity col-
umn. The purified Spa47 protein was eluted using on-column cleavage
of the intein linker domain by exposure to binding buffer containing
50 mM DTT. The elution fractions were diluted, resulting in a final
buffer concentration of 20 mM Tris, 100 mM NaCl, 5 mM DTT, pH 7.9,
supporting additional purification by anion exchange chromatography.
Wild-type Spa47 and most of the purified mutants do not bind the
anion exchange resin under these conditions, resulting in purified
Spa47 in the flow through. Spa47R271E bound the anion exchange col-
umn tightly and was eluted using a 100 mM to 1 M NaCl elution gradi-
ent. The purified Spa47 was concentrated using Sartorius centrifugal
filter units with a 30 kDa molecular weight cutoff and further
purified/characterized using a Superdex 200 16/600 size exclusion col-
umn equilibrated with 20 mM Tris, 100 mM NaCl, 5 mM DTT, pH 7.9
followed by SDS-PAGE. Spa47 concentrations were determined using
in gel densitometry of Coomassie stained acrylamide gels and bovine
serum albumin as a standard, as previously reported and validated.16 All
Spa47 concentrations are reported in monomer concentration units for
consistency and clarity.
2.4 | Spa47 crystallization
Crystallization of engineered Spa47Δ1-79 point mutation variants was
performed using standard vapor diffusion methods in conditions simi-
lar to those previously identified for the wild-type Spa47Δ1-79 con-
struct.15 For each construct, drops containing 3 μL protein
(10-20 mg/mL) and 1 μL well solution were set up by hanging drop
vapor diffusion with well conditions containing 0.1 M Tris pH 8.5,
0.2 M ammonium acetate, 0.2 M lithium sulfate, 20% - 26% PEG
4000, and 5.5% - 10.5% MPD. Small rod-like crystals were observed
after approximately eight hours at room temperature (20-22C).
2.5 | Crystallographic data collection and structure
determination
Crystallographic data for each Spa47Δ1-79 point mutation variant were
collected on beamlines 9-2 and 14-1 at the Stanford Synchrotron
Radiation Lightsource. Data were processed using HKL2000.20 The
crystals belong to space group P 21 and contain two molecules in
the asymmetric unit (Matthews coefficient = 2.3, 45% solvent). The
structures were solved by molecular replacement using the publi-
shed wild-type Spa47Δ1-79 structure (PDB ID 5SWJ) as the search
model. PHENIX21 was used to perform individual b-factor, posi-
tional, and TLS refinement. Final refinement statistics are shown
for each structure in Supplementary Table S1.
2.6 | Size-exclusion chromatography evaluation of
Spa47 oligomerization
Wild-type Spa47 and each of the engineered Spa47 mutants were
expressed and purified as described above. Spa47 was purified from
one-liter cultures and concentrated to 1 mL prior to filtration to
remove any insoluble components, and the protein was then evalu-
ated using a GE Superdex 200 16/600 size exclusion column. The col-
umn was preequilibrated with 20 mM Tris, 100 mM NaCl, 5 mM DTT,
pH 7.9, and operated at 0.5 mL/min. A280 elution profiles were gener-
ated and used to visualize the distribution of monomeric and oligomeric
species of the Spa47 proteins. The elution profiles were normalized to
the maximum absorbance value for each of the constructs and baseline
corrections, and smoothing functions were performed on each of the
chromatograms.
2.7 | Shigella invasion of epithelial cells
Invasion phenotype of S. flexneri strains expressing the engineered
Spa47 mutants were determined by a gentamicin protection assay as
previously described.22 Sterile 24-well plates were seeded with pas-
saged HeLa cells and grown overnight in DMEM supplemented with
10% fetal calf serum, penicillin, and streptomycin at 100% relative
humidity, 37C, and 5% CO2. Evaluated S. flexneri strains were streaked
onto tryptic soy agar (TSA) plates containing 0.025% Congo Red and
grown overnight at 37C. Small cultures containing appropriate antibi-
otics were inoculated from the agar plates and grown to and OD600 of
0.6 at 37C and 200 rpm. Equivalent bacterial loads were introduced
to the cultured HeLa cells, and the plates were centrifuged at 1000 × g
for 5 minutes to synchronize contact between the bacteria and HeLa
cells. The inoculated cells were incubated at 37C for 30 minutes,
rinsed to remove extracellular bacteria, and treated with 50 μg/mL
gentamicin to selectively kill the Shigella that had not successfully
invaded the HeLa cells. The HeLa cells were then lysed with 1%
agarose in water and overlaid with a LB agar solution. Overnight
incubation at 37C resulted in Shigella colony formation from the
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previously internalized bacteria, supporting a quantitative compari-
son of invasion phenotype among the tested Shigella strains.
2.8 | Shigella-induced erythrocyte hemolysis
The effects of the engineered Spa47 mutations on T3SS-mediated
hemolysis of red blood cells were determined using a slightly modified
version of a previously described method.23 Briefly, S. flexneri
expressing wild-type Spa47 or the Spa47 mutants described in this
study were grown overnight on TSA-Congo Red plates, and a small
number of isolated colonies were used to inoculate 10 mL of tryptic
soy broth containing appropriate antibiotics. The cultures were grown
to an OD600 of ~1.0, collected by centrifugation, and gently
resuspended in 200 μL PBS. Then 50 μL of each bacterial mix was com-
bined with 5 × 108 red blood cells in a 96-well microtiter plate and
centrifuged at 2300 × g for 15 minutes to initiate contact between the
bacteria and the red blood cells. The plate was then incubated at 37C
for 1 hour and the bacteria/red blood cell mix was resuspended follow-
ing the addition of 100 μL of 4C PBS. The resuspended mix was cen-
trifuged at 2300 × g and 10C for 15 minutes to separate cellular
components and the hemoglobin that was released following red blood
cell lysis. The levels of released hemoglobin in the supernatant were
quantified by measuring absorbance at 545 nm and compared with the
released hemoglobin levels resulting from S. flexneri expressing wild-
type Spa47.
2.9 | Quantitation of S. flexneri T3SS activation and
translocator secretion
The small diazo dye Congo Red effectively induces secretion of
translocator proteins through the Shigella T3SS by mimicking the natu-
ral trigger resulting from host cell membrane interaction.24 Thus, Congo
Red exposure serves as a valuable tool that allows for concerted activa-
tion of T3SSs from Shigella strains expressing various protein mutants
such as the engineered Spa47 mutants used in this study. The Congo
Red secretion assay protocol has been described in detail elsewhere.25
Briefly, a S. flexneri strain lacking the gene for Spa47, a strain expressing
wild-type Spa47, and strains expressing the engineered Spa47 mutants
evaluated in this study were grown overnight on TSA-Congo Red plates
and a small number of isolated colonies were used to inoculate 10 mL
of tryptic soy broth containing appropriate antibiotics. Cultures were
grown at 37C to an OD600 of ~1.0 before they were cooled on ice to
temporarily slow protein expression and secretion. The cultures were
centrifuged and rinsed to separate bacteria from the culture superna-
tant and any effector proteins that had been secreted up to this point.
The cells were then resuspended in sodium phosphate buffer con-
taining 0.28 mg/mL Congo Red and were incubated at 37C for 1 hour
to promote active type three secretion. Cultures were then chilled on
ice for 5 minutes to prevent further secretion and the bacteria were
separated from the protein-containing supernatant by centrifugation
at 13000 × g for 15 minutes at 4C. The secreted proteins within
the supernatant from each strain were separated using SDS-PAGE,
transferred to PVDF membranes by Western blot, and probed using
anti-IpaC rabbit polyclonal antibodies and an Alexa 647 goat anti-rabbit
secondary antibody. Secreted IpaC levels were detected and compared
using a Bio-Rad ChemiDoc imaging system and the associated Image
Lab analysis software. As validated previously,26 a monoclonal antibody
against the cytoplasmic enzyme glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as a control in the Western blot to ensure
that the proteins observed in the supernatant were secreted from the
bacteria and were not the result of cell lysis.
2.10 | Spa47 ATP hydrolysis assay
A radioactive α-32P-ATP multiple time point activity assay was used to
determine reaction rates for all of the engineered Spa47 mutants in
monomeric and oligomeric state. The assay was carried out as described
previously.27 Briefly, the ATPase reactions were initiated at room temper-
ature (20-22C) by combining protein samples with a prepared ATP solu-
tion resulting in a final concentration of 15 mM Tris (pH 7.9), 75 mM
NaCl, 10 mMMgCl2, 1 mM cold ATP, and 0.5 μCi (300 nM) α-32P-ATP.
Samples were removed from the reaction mixture at defined time points
and the reactions rapidly quenched with a final concentration of 250 mM
ethylenediaminetetraacetic acid (EDTA). The level of ATP hydrolysis at
each time point was quantified by separating the unreacted α-32P-ATP
substrate and the α-32P-ADP product by TLC followed by exposure to a
phosphor imaging screen and detection of 32P activity with a Storm Pho-
sphorImager (Molecular Dynamics). The concentration of ADP formed
was quantified using ImageQuant software (Molecular Dynamics) and
plotted as a function of reaction time to provide a rate of ATP hydrolysis
for each enzyme under each condition tested. The final concentration of
Spa47 in all reaction conditions was held constant at 0.5 μM.
3 | RESULTS
3.1 | Predicting intermolecular interactions essential
for Spa47 oligomerization and activation
An energy minimized model of an activated Spa47 homo-hexamer
was generated by aligning the recently solved 2.15 Å Spa47K165A
structure (PDB ID 5SYP) to each of the protomers of the 2.8 Å
hetero-hexameric F1 α3β3 ATP synthase structure (PDB ID 1BMF)
using PyMOL,28 as described previously.15 The interfaces of adjoining
Spa47 protomers within the model were manually searched for inter-
actions that may be involved in supporting Spa47 oligomerization and
activation. Two such sites were identified at each interface where res-
idues from one protomer extend across the interface to potentially
interact with oppositely charged amino acids from the adjacent proto-
mer (Figure 1), driving and/or stabilizing homo-oligomerization and
activation of Spa47. For simplicity, the site containing R271, R272,
and E267 that is located near the pore of the hexameric structure will
be referred to as “Site 1” (Figure 1A) and the region containing R189,
R191, and E287 buried more deeply in the protomer interfaces and
located near the active site will be referred to as “Site 2” (Figure 1B).
A Clustal Omega sequence alignment of Spa47 and several related
T3SS ATPases identifies 100% conservation of all three Site 2 residues
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F IGURE 1 Energy minimized homo-hexameric Spa47 model predicts multiple intermolecular interactions critical for oligomerization and
activation. A, Spa47K165A (PDB: 5SYP) was modeled as an activated homo-hexamer, based on the hexameric F1 ATP synthase structure (PDB:
1BMF). Each Spa47 monomer subunit is colored independently, while residues in Site 1 are colored in green. The insert provides a closer view of
the Site 1 residues with E267 from one protomer and residues R271 and R272 from an adjacent protomer spanning the interface. B, The Spa47
homo-hexamer model is rotated down 90 and all but two of the protomers are removed for clarity. Site 2 residues within the remaining interface
are colored in yellow and a black star locates the approximate position of the interfacial active site. The insert shows a closer view of the residues
within Site 2 with R189 and R191 from one protomer directed across the interface toward E287 of the adjacent protomer. C, Protein sequence
alignment of several T3SS ATPases was performed using the Uniprot multiple sequence alignment tool, Clustal Omega, with single fully
conserved residues (*), conservation between groups with strongly similar properties (:), and weakly similar properties (.) identified. Alpha helix
and beta sheet regions, as predicted by the PSIPRED structure prediction server, are color coded red and blue, respectively. Predicted Walker A
(P-loop) and Walker B regions are identified, and the Site 1 and Site 2 residues targeted for mutation are identified using solid and dashed boxes,
respectively. Uniprot accession numbers used for sequence alignment are Q6XVW8, B5RDL8, P40290, Q7DB71, P74857, F8KX49, and P26465
for Spa47, InvC, YscN, EscN, SsaN, CdsN, and FliI, respectively
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(Figure 1C). Site 1, however, shows full conservation of the identified
glutamate, but the arginines in Spa47 are both only conserved in the
T3SS ATPases InvC from Salmonella and YscN from Yersinia.
3.2 | Engineered Spa47 site 1 and site 2 mutants
maintain overall structural integrity
The N-terminal 79 residues were removed from each of the Spa47 pro-
teins to promote crystallization, resulting in 1.85 - 3.00 Å structures for
10 of the 13 engineered Spa47 mutants (Supplementary Table S1 and
Supplementary Figure S1). Each of the determined structures closely
resemble the wild-type Spa47 structure, with Cα RMSD values ranging
from 0.31 to 0.45 Å (Figure 2 and Supplementary Figure S1). Thus, the
mutations in the ten crystallized constructs do not appear to impact the
local or global protein structures, suggesting that changes observed in
Spa47 activity, oligomer formation, and Shigella virulence phenotype
(described below) are due to changes in sidechain characteristics.
3.3 | Identified Spa47 residues are critical for proper
oligomer formation
Spa47 oligomerization is essential for ATPase activity and Shigella viru-
lence, therefore, it was hypothesized that the predicted intermolecular
interactions shown in Figure 1 may play important roles in forming
and/or stabilizing Spa47 homo-oligomers. Size exclusion chromatogra-
phy has been a valuable tool in characterizing Spa47 oligomerization
and was used here to determine the effect of mutating residues
within Site 1 and Site 2 to either alanine or to an opposite charged
residue (Figure 3). While mutating E267 within Site 1 to either ala-
nine or arginine has no effect on oligomerization, mutating either
R271 or R272 to glutamate significantly reduces the ability for the
mutant to form stable oligomers (Figure 3A). Mutating either R271
or R272 to alanine, however, eliminates oligomer formation alto-
gether. Looking at the highly conserved Site 2 shows that mutations
to R189 and E287 reduce oligomerization, while all tested mutations
targeting R191 abolished Spa47 oligomerization (Figure 3B), con-
firming that the predicted Site 2 residues all play an important role in
Spa47 oligomerization.
3.4 | Identified interfacial Spa47 residues influence
ATPase activity
We have previously shown that stable Spa47 oligomers exhibit signifi-
cantly enhanced ATPase activity compared to isolated monomeric
Spa47 due to the contribution of active site residues from adjacent
protomers upon oligomerization.15 It seems that transient oligomeri-
zation accounts for the low level activity observed for isolated Spa47
monomers, likely utilizing an identical hydrolysis mechanism, but now
relying on the formation of a short-lived productive Spa47X/ATP com-
plex. The effect of each of the engineered Site 1 and Site 2 mutations
on Spa47 ATPase activity was determined using a radioactive α-32P-
ATP multiple time point activity assay (Figure 4). The activity results
show that the full-length wild-type monomeric and oligomeric Spa47
species behaved as previously reported,15 hydrolyzing ATP at rates of
0.20 ± 0.08 (μmol ADP/min)/mg Spa47 and 1.26 ± 0.22 (μmol
ADP/min)/mg Spa47, respectively. All tested mutations within Site
2 (R189, R191, R189/R191, and E287) abolished ATPase activity
regardless of ability to form stable oligomeric species. Interestingly,
mutations to the less conserved Site 1 residues, including E267, R271,
and R272, had a wider range of effects on the ability of Spa47 to
hydrolyze ATP and did not fully eliminate activity of any of the con-
structs. The alanine and arginine mutations to E267 both maintained
the ability to form stable oligomers, however, the mutated oligomers
exhibited ATPase activity levels similar to the respective monomers,
suggesting that E267 is not essential for stable oligomer formation,
but is perhaps necessary for stabilizing the protomer interface to sup-
port proper Spa47 ATPase activity. While the R271A and R272A Site
2 mutants both eliminated oligomerization, the monomers continued
to function at levels similar to the wild-type monomer (0.20 ± 0.04
(μmol ADP/min)/mg Spa47 and 0.33 ± 0.16 (μmol ADP/min)/mg
Spa47, respectively). The R271E mutant maintained wild-type mono-
mer ATPase levels but attenuated oligomer activity, while the R272E
mutation surprisingly maintained wild-type levels for both monomeric
and oligomeric species (0.31 ± 0.22 (μmol ADP/min)/mg Spa47 and
1.02 ± 0.28 (μmol ADP/min)/mg Spa47, respectively).
F IGURE 2 High-resolution crystal structures of engineered Spa47
oligomerization mutants. Alignment of the previously solved wild-type
Spa47Δ1–79 structure (gray, PDB ID 5SWJ) to each of the ten
Spa47Δ1–79 point mutant structures solved in this study (structure
coloration is consistent with that used in Supplementary Figure S1)
[Color figure can be viewed at wileyonlinelibrary.com]
936 DEMLER ET AL.
3.5 | Predicted interfacial Spa47 residues support
overall Shigella virulence phenotype
Insertion of the T3SS translocator tip proteins IpaB and IpaC into the
host cell membrane forms the translocon pore and ultimately allows
secretion of effector proteins into eukaryotic host cell cytoplasm.29-32
Secretion of these effectors into the host cell supports invasion of the
infected host cell, escape from the resulting vacuole, and evasion of host
immune responses.4,33,34 To better understand the molecular details of
Spa47-mediated Shigella virulence, the effect of the engineered Spa47
Site 1 and Site 2 mutations on Shigella virulence phenotype were tested
using red blood cell hemolysis and gentamicin protection (cellular inva-
sion) assays (Figure 5). With the exception of the R191E and E287A
mutations, each of the Site 2 mutations essentially abolished invasion
and hemolysis phenotype, consistent with the lack of in vitro ATPase
activity observed for these mutants (Figure 4). Surprisingly, even though
no ATPase activity was observed in vitro for the Spa47 R191E and
E287A mutants, Shigella expressing these mutants exhibited moderate
invasion and hemolysis levels when compared to Shigella expressing
wild-type Spa47, suggesting that additional interactions provided within
the T3SA sorting platform must partially mitigate the effects of these
mutations in vivo. Shigella expressing the Spa47 Site 1 mutations E267A,
E267R, and R271A showed at or near wild-type levels of hemolysis
(116 ± 12%, 108 ± 8%, and 91 ± 19%, respectively) and invasion
(66 ± 23%, 54 ± 7%, and 92 ± 15%, respectively). Despite forming only
monomers in vitro, the R272A mutant supported 32 ± 7% invasion and
18 ± 6% hemolysis phenotypes, respectively. The R271E and R272E
mutants both resulted in severely attenuated levels of both invasion and
hemolysis, despite robust in vitro ATPase activity profiles for both mono-
meric and oligomeric species.
3.6 | IpaC secretion profiles provide insight into the
effects of engineered Spa47 mutations on T3SS
activity and Shigella virulence
While the specific mechanism remains unclear and somewhat contro-
versial, Spa47 catalyzed ATP hydrolysis is required for efficient
F IGURE 3 Engineered Spa47 mutations negatively impact homooligomer formation. Size-exclusion chromatography analysis of purified Site
1 (A) and Site 2 (B) Spa47 mutants. The chromatograms from each Spa47 mutant are normalized to the A280 absorbance of the wild-type Spa47
monomer peak eluting at approximately 79 mL. The chromatograms have been further divided into those resulting in detectable levels of Spa47
oligomer formation (top) and those resulting from mutations that eliminated oligomerization (bottom). The void volume (Vo) of the column is
39.8 mL and is located with an arrow [Color figure can be viewed at wileyonlinelibrary.com]
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protein secretion through the associated needle and tip complex of the
Shigella T3SA. To determine the effect that the tested Spa47 mutations
had on the ability of Shigella to actively secrete effector proteins
through the T3SA, the levels of the secreted Shigella translocator pro-
tein IpaC were quantified following Congo Red activation of Shigella
strains expressing each of the engineered Spa47 Site 1 and Site
2 mutants (Figure 6). Consistent with the hemolysis and invasion results
in Figure 5, the Spa47 Site 2 mutants significantly attenuated or elimi-
nated IpaC secretion through the apparatus. The Shigella strains
expressing Spa47 R191E and Spa47 E287A resulted in low, but detect-
able secretion levels of IpaC (11% ± 2% and 27% ± 6%, respectively).
Low levels of secreted IpaC were also observed for Shigella expressing
the Site 1 Spa47 mutants R271E, R272A, and R272E, again tracking
well with the hemolysis and invasion phenotypes observed for these
strains (Figure 5). Wild-type levels of IpaC secretion were observed for
the Shigella strain expressing the Spa47 R271A mutant while the
E267A and E267R mutations unexpectedly increased IpaC secretion
levels to 233% ± 48% and 146% ± 15% of wild-type. These enhanced
secretion levels likely support the robust invasion and hemolysis pheno-
types of these mutants despite low level ATPase activity observed for
the purified mutant oligomers in vitro. With the IpaC secretion profiles
in good agreement with the observed Shigella virulence phenotypes, it
seems clear that the ability of the Shigella strains to secrete protein
effectors is directly correlated with Spa47 ATPase activity and that
several of the identified Spa47 Site 1 and Site 2 residues are essential
for proper T3SS effector secretion and Shigella virulence.
4 | DISCUSSION
T3SS are critical virulence factors for a broad class of Gram-negative
pathogens, driving significant efforts over the past three decades to
uncover their structure, function, activation mechanism(s), and regulatory
pathway(s). One mechanistic detail of particular interest is uncovering
specifically where the energy comes from that supports protein unfolding
and secretion through the narrow apparatus needle. Work primarily
focusing on the flagellar T3SS suggests that secretion is driven by proton
motive force (PMF) that is coupled to protein secretion through an export
gate in the basal body that acts as a proton/protein antiporter.35-37 While
the influence of an electrochemical gradient can certainly not be ruled
out, expression of non-catalytic Spa47 mutants eliminates effector secre-
tion and pathogen virulence in Shigella, suggesting that at least Shigella
type three secretion is either independent of PMF and solely reliant on
ATP hydrolysis, or more likely that the effects of ATP hydrolysis and
F IGURE 4 Kinetic analysis of ATP hydrolysis by each of the
engineered Spa47 constructs used in this study. Isolated wild-type
monomeric and oligomeric Spa47 are both active, with the oligomeric
species (black bar) resulting in a significantly enhanced rate of
hydrolysis compared to the monomeric form (gray bar). ATP
hydrolysis rates were additionally determined for isolated monomeric
and oligomeric forms (when available) for all engineered Site 1 and
Site 2 Spa47 mutants. Each data set represents the mean ± S.D. of
three independent kinetic experiments from two independent protein
preparations. (*) Indicates a statistical significance compared to the
appropriate oligomer state of wild-type Spa47 (one-way ANOVA
followed by a Dunnett's post test, P ≤ 0.05))
F IGURE 5 Effect of engineered Spa47 salt bridge mutations on
Shigella virulence phenotype. The ability of the Shigella mutants to
invade eukaryotic host cells was measured by a standard gentamicin
protection assay. Invasion results (shown in black) are presented as
the percentage of invasion by a S. flexneri strain expressing wild-type
Spa47 and represent at least three independent experimental data
sets spanning two biological replicates. The impact of each Spa47
mutant has on Shigella's ability to disrupt phospholipid membranes
was examined using a hemolysis assay that quantifies released
hemoglobin following incubation of red blood cells with the described
Shigella mutants. Hemolysis results (shown in gray) are presented as a
percentage of the hemoglobin released by the S. flexneri strain
expressing wild-type Spa47 and result from at least six experiments
spanning two biological replicates. Invasion and hemolysis data are
both presented as mean values ± S.D. (*) Indicates statistical
significance compared to the wild-type Spa47 strain (one-way
ANOVA followed by a Dunnett's posttest, P ≤ 0.05))
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PMF are synergistic.15,16 What is clear, however, is that the Shigella T3SS
relies on Spa47 catalyzed ATP hydrolysis, suggesting that Spa47 may be
involved with in vivo activation and regulation of the Shigella T3SS and is
an attractive target for the development of non-antibiotic small molecule
therapeutics.
Like the catalytic hetero-hexameric F1 and V1 ATPases, activation
of T3SS ATPases requires oligomerization to complete interfacial active
sites in the complex. In contrast to the presumably more evolved
hetero-hexameric F1 and V1 ATPases, however, all enzymatically char-
acterized examples of T3SS ATPases form homo-oligomers.16,38-43
In vitro studies of T3SS ATPases have identified active complexes rang-
ing from homo-trimers to homo-dodecamers, though cryo-electron
imaging of T3SSs from Shigella and Salmonella both suggest that homo-
hexameric T3SS ATPases reside at the base of the apparatus
in vivo.10,14 Regardless, the importance of oligomerization in activation
of T3SS ATPases such as Spa47 underscores the need to better under-
stand not only the specific mechanism of ATP hydrolysis, but also the
molecular basis of oligomerization itself.
The work presented here provides insight into Spa47 oligomer
formation by identifying two independent sites at the interface of
Spa47 protomers that support stable Spa47 oligomer formation, enzy-
matic activation of isolated Spa47, protein secretion through the
T3SA, and overall Shigella virulence. Mutating R271 or R272 from Site
1 to alanine or R191 from Site 2 to either alanine or glutamate
prevented stable Spa47 oligomerization altogether (Figure 3 and Sup-
plementary Table S2). Interestingly, none of the tested mutations to
E267 (Site 1) affected oligomerization while the R271E and R272E
reduced, but did not eliminate, Spa47 oligomer formation. All of the
tested mutations to Site 2 residues, on the other hand, reduced or
eliminated oligomerization, suggesting that while both identified sites
play important roles in Spa47 oligomerization, Site 2 has a stronger
influence, consistent with the fact that each of the identified Site
2 residues are fully conserved among several well-studied T3SS
ATPases (Figure 1C). The influence of the tested Site 1 and Site
2 mutations on enzyme function was demonstrated with an ATPase
activity assay, where the mutants targeting Site 1 residues exhibited
varying degrees of ATPase activity while ATPase activity of each of
the Site 2 mutants was essentially eliminated. In vivo testing of Shi-
gella virulence and T3SS-mediated effector secretion also showed the
strongest influence by Site 2 mutants, with six of the eight tested
Spa47 Site 2 mutants unable to disrupt red blood cell membranes or
infect cultured eukaryotic cells. Not surprisingly, these virulence phe-
notypes correlate quite well with T3SS effector protein (IpaC) secretion
levels, showing that protein secretion is linked to Spa47 catalyzed ATP
hydrolysis and that Shigella virulence is driven by protein secretion
through the T3SA. Surprisingly, despite being ATPase inactive
in vitro, the Site 2 Spa47 R191E and E287A mutants exhibited mod-
est, yet robust, invasion, hemolysis, and effector secretion capabili-
ties, suggesting that additional interactions within the T3SA can
overcome the effects of these mutations and support Spa47 oligo-
merization/activation in vivo. While the data reported in this study
clearly show that the identified Spa47 interfaces are involved in
supporting oligomerization and ATPase activity, specific molecular
insight into the intermolecular interactions involving the Site 1 and
Site 2 residues was unavailable until Majewski and colleagues publi-
shed a 3.3 Å cryo-EM structure of the E. coli homo-hexameric T3SS
ATPase EscN during the preparation of this manuscript.44
The cryo-EM structure of EscN is currently the only high-
resolution structure available for an activated homo-hexameric
T3SS ATPase, providing valuable insight into the conformational
changes and intermolecular interactions responsible for ATP hydro-
lysis and a structural rationale for the effects observed in the
Spa47 mutants engineered in this study. Specifically, the homo-
hexameric EscN structure includes the central stalk protein EscO as
well as the transition state analog Mg2+ ADP-AlF3 in four of the
six EscN protomer interfaces, displaying conformational changes
reminiscent of those supporting ATP synthesis/hydrolysis in rotary
F IGURE 6 Immunoblot analysis of Congo Red-induced T3SS
secretion profiles for engineered Spa47 mutant Shigella strains. The
levels of IpaC actively secreted following Congo Red induction were
compared for Shigella strains expressing the Spa47 salt bridge mutants
as well as positive and negative controls expressing wild-type Spa47
and a Spa47 null strain, respectively. A, Actively secreted IpaC was
detected by Western blot and levels compared using fluorescence
densitometry. The cytoplasmic enzyme GAPDH was observed in the
whole cell extracts (WCE) but not in the supernatant containing the
secreted IpaC protein. B, The secreted IpaC levels are reported
relative to a S. flexneri strain expressing wild-type Spa47. The
reported values represent the means ± SD from three independent
analyses and two biological replicates. (*) indicates statistical
significance compared to the wild-type Spa47 strain (one-way
ANOVA followed by a Dunnett's posttest, P ≤ 0.05))
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F- and V-type hetero-hexameric ATPases.44 Superposition of nucleotide-
free and nucleotide bound active sites reveals significant conformational
rearrangements at the protomer interface (Figure 7, stereo image). The
transition from nucleotide-free to nucleotide-bound states involves a
shift of up to 7 Å between individual monomers at the interface. The shift
engages an intermolecular hydrogen bonding network that includes Site
2 residues. Two of these hydrogen bonds are observed between the
EscN R209 (R191 in Spa47) and D340 (D324 in Spa47) sidechains, and
between the sidechain of E304 (E287 in Spa47) and the backbone of
G208 (G190 in Spa47). As a consequence, R207 (R189 in Spa47) is posi-
tioned to coordinate the gamma phosphate of ATP, presumably facilitat-
ing phosphate hydrolysis. This is in good agreement with the results
presented here as all of the tested mutations to Spa47 R189 lacked
ATPase activity and exhibited avirulent phenotypes while Shigella strains
expressing mutations to the conserved R191 and E287 residues ranged
from avirulent to modestly virulent depending on the identity of the
mutation.
Together, the findings presented here have identified two inde-
pendent sites that reside at the interface between Spa47 protomers
to support oligomerization and activation of Spa47, protein secretion
through the T3SA, and overall Shigella virulence. Insights from a
recently solved EscN homo-hexameric cryo-EM structure suggest that
the Site 2 residues directly influence ATP hydrolysis in addition to
supporting oligomerization, while the Site 1 residues are located much
further from the active site and are likely not directly involved in catal-
ysis, but do contribute intermolecular hydrogen bonds that support
oligomer formation and stabilize local structural elements. Fully
understanding the influences of the identified residues on Spa47
activity and type three secretion will likely require a series of bio-
chemical and biophysical studies spanning T3SS ATPases from other
pathogens as well as structural and perhaps single molecule fluores-
cence studies. Predicting and characterizing the influence of the
tested mutations in this study, however, begins to paint a picture of
how Spa47 is activated and uncovers much needed targets for non-
antibiotic small molecule therapeutics that should inhibit Spa47
ATPase activity and may be effective in targeting the conserved sites
of additional T3SS ATPases such as EscN.
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